叶酸联合降压药物治疗H型高血压的临床分析
|
摘要
目的研究叶酸联合降压药物治疗H型高血压的临床效果。方法 100例H型高血压患者,随机分为对照组和试验组,各50例。对照组使用常规降压药物治疗,试验组使用叶酸联合降压药物治疗。比较两组治疗前后血压、血浆同型半胱氨酸(Hcy)水平及不良事件发生情况。结果治疗后,试验组患者收缩压、舒张压和血浆Hcy水平分别为(125.62±6.94)mm Hg(1 mm Hg=0.133 kPa)、(81.22±6.42)mm Hg、(7.05±1.96)μmol/L,均显著优于对照组的(134.28±6.86)mm Hg、(88.65±5.94)mm Hg、(13.25±2.08)μmol/L,差异均有统计学意义(P<0.05)。试验组患者不良事件发生率8.00%显著低于对照组的26.00%,差异有统计学意义(P<0.05)。结论叶酸联合降压药物治疗H型高血压的效果显著,能有效改善患者的血压和血浆Hcy水平,降低患者心脑血管不良事件发生率,具有较高的临床应用价值。
Objective To study the clinical effect of folic acid combined with antihypertensive drugs in the treatment of H-type hypertension. Methods A total of 100 H-type hypertension patients were randomly divided into control group and experimental group, with 50 cases in each group. The control group was treated with conventional antihypertensive drugs, and the experimental group was treated with folic acid and antihypertensive drugs. Comparison were made on blood pressure, plasma homocysteine(Hcy) level and adverse events before and after treatment between the two groups. Results The experimental group had significantly better systolic blood pressure, diastolic blood pressure and plasma Hcy levels respectively as(125.62±6.94) mm Hg(1 mm Hg= 0.133 kPa),(81.22±6.42) mm Hg and(7.05±1.96) μmol/L than(134.28±6.86) mm Hg,(88.65±5.94) mm Hg and(13.25±2.08) μmol/L in the control group, and their difference was statistically significant(P<0.05). The experimental group had significantly lower incidence of adverse events as 8.00% than 26.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion Combination of folic acid and antihypertensive drugs shows a significant effect on the treatment of H-type hypertension, and it can effectively improve the blood pressure and plasma Hcy level of patients, and reduce the incidence of cardiovascular and cerebrovascular adverse events. It has a high clinical application value.
Objective To study the clinical effect of folic acid combined with antihypertensive drugs in the treatment of H-type hypertension. Methods A total of 100 H-type hypertension patients were randomly divided into control group and experimental group, with 50 cases in each group. The control group was treated with conventional antihypertensive drugs, and the experimental group was treated with folic acid and antihypertensive drugs. Comparison were made on blood pressure, plasma homocysteine(Hcy) level and adverse events before and after treatment between the two groups. Results The experimental group had significantly better systolic blood pressure, diastolic blood pressure and plasma Hcy levels respectively as(125.62±6.94) mm Hg(1 mm Hg= 0.133 kPa),(81.22±6.42) mm Hg and(7.05±1.96) μmol/L than(134.28±6.86) mm Hg,(88.65±5.94) mm Hg and(13.25±2.08) μmol/L in the control group, and their difference was statistically significant(P<0.05). The experimental group had significantly lower incidence of adverse events as 8.00% than 26.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion Combination of folic acid and antihypertensive drugs shows a significant effect on the treatment of H-type hypertension, and it can effectively improve the blood pressure and plasma Hcy level of patients, and reduce the incidence of cardiovascular and cerebrovascular adverse events. It has a high clinical application value.
引文
[1]薛松,陈艳丽,李群,等.老年H型高血压发病率及高同型半胱氨酸血症的治疗观察.中西医结合心血管病电子杂志, 2018,6(8):72-73.
[2]冯立春.叶酸联合降压药物治疗H型高血压效果分析.新乡医学院学报, 2018, 35(3):196-200.
[3]苏冠春.小剂量叶酸片对社区H型高血压患者血清同型半胱氨酸水平及血压的影响.实用心脑肺血管病杂志, 2017, 25(6):150-152.
[4]辛庆锋,孙有利,丁红玲.依那普利叶酸片对H型高血压患者血浆Hcy、血压和颈动脉粥样硬化斑块的影响.社区医学杂志,2017(1):39-41.
[5]田井强,曾恋.叶酸对H型高血压患者Hcy水平及心血管意外发生的影响研究.当代医学, 2016, 22(13):36-37.
[6]黄鑫涛,庞学民,李之恒,等.同型半胱氨酸水平对H型高血压患者预后影响的临床研究.中国实用医刊, 2015(13):88-89.
[7]王博,沈滔,毛蕾,等.依那普利叶酸片对伴发H型高血压的急性脑梗死患者预后的影响.世界临床药物, 2017(10):680-686.
[8]池学洋.叶酸干预治疗对H型老年高血压患者血浆同型半胱氨酸水平和主要心血管事件的影响研究.北方药学, 2015(11):95-97.
[9]李芙蓉,谢春苹.叶酸对H型高血压同型半胱氨酸水平和颈动脉内膜中层厚度的影响.中国药物经济学, 2013(3):137-139.
[10]吕海权,雷敏,陆敏,等. H型高血压对冠心病患者预后的影响.中国动脉硬化杂志, 2016, 24(4):396-400.
[2]冯立春.叶酸联合降压药物治疗H型高血压效果分析.新乡医学院学报, 2018, 35(3):196-200.
[3]苏冠春.小剂量叶酸片对社区H型高血压患者血清同型半胱氨酸水平及血压的影响.实用心脑肺血管病杂志, 2017, 25(6):150-152.
[4]辛庆锋,孙有利,丁红玲.依那普利叶酸片对H型高血压患者血浆Hcy、血压和颈动脉粥样硬化斑块的影响.社区医学杂志,2017(1):39-41.
[5]田井强,曾恋.叶酸对H型高血压患者Hcy水平及心血管意外发生的影响研究.当代医学, 2016, 22(13):36-37.
[6]黄鑫涛,庞学民,李之恒,等.同型半胱氨酸水平对H型高血压患者预后影响的临床研究.中国实用医刊, 2015(13):88-89.
[7]王博,沈滔,毛蕾,等.依那普利叶酸片对伴发H型高血压的急性脑梗死患者预后的影响.世界临床药物, 2017(10):680-686.
[8]池学洋.叶酸干预治疗对H型老年高血压患者血浆同型半胱氨酸水平和主要心血管事件的影响研究.北方药学, 2015(11):95-97.
[9]李芙蓉,谢春苹.叶酸对H型高血压同型半胱氨酸水平和颈动脉内膜中层厚度的影响.中国药物经济学, 2013(3):137-139.
[10]吕海权,雷敏,陆敏,等. H型高血压对冠心病患者预后的影响.中国动脉硬化杂志, 2016, 24(4):396-400.